Doc description: Information Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number 10575977

Filing Date 2007-05-02

First Named Inventor Haijun Sun

Art Unit 1647

Examiner Name DEBERRY, Regina M

Attorney Docket Number X-18530

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Document		s,Columns,Lines where ant Passages or Relevar es Appear			
	1										
If you wisl	h to ad	d additional & S. Pate	ent citatio	n inform	ation pl	ease click the	Add button.	•	Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite N	Publication Kind Publication Number Date		of sited Document			es,Columns,Lines where vant Passages or Relevant res Appear				
	1		DUPI	ICATE							
If you wisl	h to ad	d additional U.S. Pub	lished Ap	plication	citation	oformation p	lease click the Ad	d button	Add		
				FOREIC	N PAT	ENTROCUM	ENTS		Remove		
Examiner Initial*				Kind Code ⁴	Publication Applicant of cited Date			vhere Rel	or Relevant	T5	
	1										
If you wisl	h to ad	d additional Foreign F	Patent Do	cument	ı citation	information pl	ease click the Add	button	Add		<u> </u>
			ИОИ	I-PATEN	IT LITE	RATURE DO	CUMENTS	THE PROPERTY OF THE PARTY OF TH	Remove		
Examiner Initials*	Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10575977		
	Filing Date		2007-05-02		
	First Named Inventor Haijur		n Sun		
	Art Unit		1647		
	Examiner Name DEBE		RRY, Regina M		
	Attorney Docket Number		X-18530		

1	ABATH and SMPSON, Peptide Research, 3(4):167-168 (1990)	
2	AUSUBEL et al., Current Protocols in Molecular Biology, 1:2.20.3, Green Publishing Associates, Inc., and John Wiley & Sons, Inc, New York (1989)	
3	BAYES et al., "Gateways To Clinical Trials." Methods and Findings in Experimental and Clinical Pharmacology, 25(6):483-506 at 491, Prous, Barcelona, Spain (July 2003)	
4	BLANCKAERT et al., "Partial characterization of endothelial FGF receptor functional domain by monoclonal antibody VBS-1. "Hybridoma and Hybridomics, 21(3): 153-159 (June 2002)	
5	BOERNER et al., J. Immunol, 147(1):86-95 (1991) DUPLICATE	
6	DIECKMANN and TZAGOLOFF, J. Biol. Chem., 260:1513-1520 (1985)	
7	FISHWILD et al., Nature Biotechnology, 14:845-51 (1996)	
8	SMITH, et al., Gene, 67:31-40 (1988)	
5	HOOGENBOOM and WINTER, J. Mol Biol., 227:381 (1991)	
10	JOHNSON et al., "The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain." Molecular and Cellular Biology, 11(9):4627-4634 (September 1991)	
11	KAUFMANN and SHARP, "Amplification and Expression of Sequences Cotransfected with A Modular Dihydorfolate Reductase Complementary DNA Gene." J. Mol. Biol., 159:601-621 (1982)	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not far submission under 37 CFR 1.99)

Application Number		10575977		
Filing Date		2007-05-02		
First Named Inventor Haijur		n Sun		
Art Unit		1647		
Examiner Name DEBE		RRY, Regina M		
Attorney Docket Number		X-18530		

12	KOSTRZEWA et al., "Genomic structure and complete sequence of the human FGFR4 gene." Mammalian Genome: Official Journal of the International Mammalian Genome Society, 3(2):131-135 (February 1998)	
13	LONBERG and AUSZAR, Intern Rev. Immunol, 13:65-93 (1995)	
14	LONBERG et al., Nature, 3 8:856-859 (1994)	
15	MARKS et al., J. Mol. Biol., 222:581 (1991)	
16	MORRISON, Nature, 368:812-813 (1994) DUPLICATE	
17	NEUBERGER, Nature Biotechnology, 14:826 (1996)	
18	PARTRIDGE et al., "Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration." Journal of Cellular Biochemistry, 78(3):487-499 (June 6, 2000)	
19	POWERS et al., "Fibroblast growth factors, their receptors and signaling." Endocrine Related Cancer, 7:165-197 at 165-197 (2000)	
20	SKAPER et al., "The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects." Journal of Neurochemistry, 75(4):1520-1527 (October 2000)	
21	SOUTHERN and BERG, J. Mol. Appl. Genet., 1:327-341 (1982)	
22	STEGER et al., "Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium." Histochemistry and Cell Biology, 110(1):57-62, Germany (1998)	

			T		T		
			Application Number		10575977		
INIESDEMA	A TION	I DISCLOSUDE	Filing Date		2007-05-02		
		N DISCLOSURE	First Named Inventor Haiju		un Sun		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Art Unit		1647		
(1101101 5/15		Tanaci or or it 1.00,	Examiner Name DEBERRY, Regina M				
			Attorney Docket Numb	er	X-18530		
	A A A A A A A A A A A A A A A A A A A						
23	rever	e al., "Monoclonal antibody sible hypophagia and weight iology Endocrinology and M	loss in rodents and monkey	/s." Am	erican Journal of		
24							
25		DUP	LICATE				
26							
If you wish to	add add	ditional non-patent literatu	re document citation info	rmation	n please click the Add button Add		
			EXAMINER SIGN	TURE			
Examiner Sig	ınature			M	Date Considered		
					mance with MPEP 609. Draw line through a through the communication to applicant.		
Standard ST.3).	³ For Japa ent by the	anese patent documents, the inc appropriate symbols as indicated	dication of the year of the reign	of the E	office that issued the document, by the two-letter code (Windown must precede the serial number of the patent doord ST.16 if possible. ⁵ Applicant is to place a check man	cument.	